Privo Technologies is a private, clinical-stage biotechnology company. It has developed the PRV111 patch, a topical and loco-regional cancer treatment designed to administer chemotherapy directly to the tumor and surrounding lymph nodes, without any systemic toxicity. The company has met the endpoints of its phase 2 clinical trial treating patients with oral cavity cancer. Results demonstrated over a 70% tumor volume reduction in less than 7 days of therapy, with no dose-limiting toxicities. Privo is currently raising funding for its phase 3 pivotal study.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2010
Main Therapeutic Focus:
Oncology
Lead Product in Development:
PRV111
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
